Meeting
2014 ASCO Annual Meeting
Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.
Authors
Safia El Messaoudi
IRCM INSERM, Montpellier, France
Safia El Messaoudi , Florent Mouliere , Caroline Mollevi , Brigitte Gillet , Michelle Nouaille , Virginie Loriot , Denis Pezet , Muriel Mathonnet , Marc Ychou , Alain Roger Thierry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3604)
DOI
10.1200/jco.2014.32.15_suppl.3604
Abstract #
3604
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
First Author: Jean-Baptiste Bachet
Poster
2018 Gastrointestinal Cancers Symposium
The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.
First Author: Kuo-Hsing Chen
Poster
2016 ASCO Annual Meeting
Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).
First Author: Krittiya Korphaisarn
Poster
2016 Gastrointestinal Cancers Symposium
![Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in <i>KRAS</i> (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].](https://d201v5jt9ylckg.cloudfront.net/173/10963/120799/120799_poster_pv.jpg)
Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].
First Author: Juan Maurel